Roche Gets CE Mark for Elecsys NfL MS Blood Test
BASEL, Switzerland, April 13, 2026 Roche has announced that its Elecsys® Neurofilament Light Chain (NfL) blood test has received...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
BASEL, Switzerland, April 13, 2026 Roche has announced that its Elecsys® Neurofilament Light Chain (NfL) blood test has received...
WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...
BASEL, Switzerland, March 30, 2026 Roche has announced the launch of its cobas® MPX-E assay, a next-generation 4-in-1 multiplex...
Basel, March 16, 2026 Roche announced the launch of a large-scale NVIDIA-powered AI factory, marking a major advancement in...
Basel, 8 December 2025 — Roche has reported three-year follow-up findings from the pivotal phase III STARGLO study, demonstrating...
Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its...
BASEL, Switzerland, Oct. 6, 2025 — Roche announced that it has received CE-mark approval for the AI-based Kidney Klinrisk...
